Komori
Share Issuance and Disposal4582SymBio Pharmaceuticals LimitedPharmaceuticals

Notice Regarding Bringing Forward the Exercise of the 66th Stock Acquisition Rights Issued Through a Third-Party Allotment

The company instructed that the exercise start date be brought forward for the 66th stock acquisition rights allocated to EVO FUND. The exercise start date will be 30 March 2026.

Worth reading
41Recurring
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
20000000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Progress report on bringing forward the exercise of stock acquisition rights with an exercise price adjustment clause

Who receives how much

20,000,000 shares (200,000 stock acquisition rights)

EVO FUND, 200,000 stock acquisition rights (20,000,000 shares)

The lower thin line represents the existing number of shares to which these shares will be added.

Terms of the stock acquisition rights
Exercise price
The stock acquisition rights have an exercise price adjustment clause; the initial exercise price and adjustment floor are Not disclosed
Exercise period
From 30 March 2026 (end date Not disclosed)
Number of Stock Acquisition Rights
Total issued: 200,000 stock acquisition rights (20,000,000 shares). The number of unexercised rights is Not disclosed
Most recent equity financing
Timing 12 August 2025 / Type Issuance of the 65th through 67th stock acquisition rights with exercise price adjustment clauses, and the 1st series unsecured straight bonds and stock acquisition rights purchase agreement (commitment issue) / Amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalProgress report on bringing forward the exercise of stock acquisition rights with an exercise price adjustment clause
Number of shares to be issued or disposed of20,000,000 shares (200,000 stock acquisition rights)
Intended allotteeEVO FUND, 200,000 stock acquisition rights (20,000,000 shares)
Exercise priceThe stock acquisition rights have an exercise price adjustment clause; the initial exercise price and adjustment floor are Not disclosed
Exercise periodFrom 30 March 2026 (end date Not disclosed)
Number of Stock Acquisition RightsTotal issued: 200,000 stock acquisition rights (20,000,000 shares). The number of unexercised rights is Not disclosed
Most recent equity financingTiming 12 August 2025 / Type Issuance of the 65th through 67th stock acquisition rights with exercise price adjustment clauses, and the 1st series unsecured straight bonds and stock acquisition rights purchase agreement (commitment issue) / Amount Not disclosed
Items this document does not state (21)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company issued the instruction to bring forward the exercise date pursuant to the purchase agreement. As conditions for bringing forward the exercise date, the holder must not possess any undisclosed insider information, and the 65th stock acquisition rights must no longer be outstanding. These conditions were satisfied on the instruction date.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Bringing Forward the Exercise of the 66th Stock Acquisition Rights Issued Through a Third-Party Allotment | SymBio Pharmaceuticals Limited (4582) timely disclosure | Komori